Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.
Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
The National Association of Manufacturers (NAM) conducted its Q3 Outlook Survey. Read more for a discussion and analysis of the results.
This on-demand session provides insight into the best practices for financial reporting, compliance and internal controls, ensuring your organization remains transparent and accountable.
This on-demand session discuss new and upcoming accounting standards issued by the Government Accounting Standards Board (GASB) that will be effective in fiscal year 2024 and the near future.
This on-demand session will help you in identifying the risks and control measures needed to ensure compliance in your grant management and administration function.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
Boards and management may want to consider how recent Fed activity, election uncertainty, and emerging ERP considerations will affect their businesses.
Explore real estate education at TCU and water management in North Texas with podcast guest, James Hill, on Weaver: Beyond the Numbers, Location Cubed.
A recent U.S. complaint highlights the growing need for health care systems to ensure physician compensation aligns with fair market value to avoid compliance risks.
1 2 3 4 5 6 22